In the FD cohort of the CAPTIVATE study, treatment-naïve patients with CLL were treated with combined ibrutinib and venetoclax given for a total of 15 cycles of 28 days; treatment was then stopped. After completion of this regimen, the rate of complete remission was 52.2% with a high number of patients achieving uMRD in the blood (77%) or bone marrow (60%). CR, complete remission; CRi, CR with incomplete bone marrow recovery; nPR, nodular partial remission; PR, partial remission. The figure has been adapted from Figures 2A and 3A in the article by Tam et al that begins on page 3278.